Shares of NASDAQ:DTIL opened at $5.70 on Friday. Precision BioSciences has a one year low of $3.61 and a one year high of $19.43. The company has a debt-to-equity ratio of 0.34, a current ratio of ...

Fintel reports that on January 10, 2025, BMO Capital upgraded their outlook for Precision BioSciences (NasdaqCM:DTIL) from ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...

Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...

BMO Capital upgraded Precision BioSciences (DTIL) to Outperform from Market Perform with an unchanged price target of $34 alter iECURE ...

Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating ...

Fintel reports that on January 10, 2025, BMO Capital upgraded their outlook for Precision BioSciences (NasdaqCM:DTIL) from Market Perform to Outperform. As of December 23, 2024, the average one ...

Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a Phase 1/ ...

(RTTNews) - Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, on Thursday, announced positive clinical efficacy data from its partner iECURE in the Phase 1/2 OTC-HOPE ...